for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-GSK Could Maximize Target of 1 Bln Adjuvant Doses Based On Trial Data

July 29 (Reuters) - GlaxoSmithKline:

* CEO SAYS UNDERLYING DEMAND FOR ALL KEY GROWTH DRIVERS REMAINS STRONG - MEDIA CALL

* CEO SAYS WE DON’T EXPECT TO PROFIT FROM COVID-19 VACCINE PARTNERSHIPS IN THE PANDEMIC PHASE - MEDIA CALL

* CEO SAYS CO HAS NOT TAKEN ANY GOVERNMENT FUNDING ON ASO3 ADJUVANT AND HAS STARTED MANUFACTURING AT RISK - MEDIA CALL

* CEO, ON 1 BILLION TARGET DOSES OF ADJUVANT, SAYS CO WILL MAXIMIZE NUMBERS BASED ON DATA FROM TRIALS - MEDIA CALL Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up